Other risk contributors include: long-standing diabetes with end-organ damage, hypertension, older age, severe sleep apnea, and any condition that predisposes to low optic nerve perfusion
As a pharmacist with over a decade of experience, I want to share a different perspective one grounded in what Ive actually seen
Large cardiovascular outcome trials with liraglutide [40], semaglutide [41], and dulaglutide [42] have shown reductions in adverse cardiovascular events and cardiovascular mortality, while the SELECT trial demonstrated a reduction in heart failure with semaglutide [43]
Typically, DSIP cycles range from days to a couple of weeks
Many people report that foods they previously craved intensely lose their appeal on GLP-1 medications